
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Acrivon Therapeutics, Inc. Common Stock (ACRV)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ACRV (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $11.17
1 Year Target Price $11.17
4 | Strong Buy |
4 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.24% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 41.84M USD | Price to earnings Ratio - | 1Y Target Price 11.17 |
Price to earnings Ratio - | 1Y Target Price 11.17 | ||
Volume (30-day avg) 9 | Beta 1.67 | 52 Weeks Range 1.05 - 10.00 | Updated Date 08/29/2025 |
52 Weeks Range 1.05 - 10.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.24 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -1.09 | Actual -0.55 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.32% | Return on Equity (TTM) -47.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -92323993 | Price to Sales(TTM) - |
Enterprise Value -92323993 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.43 | Shares Outstanding 31455600 | Shares Floating 16683445 |
Shares Outstanding 31455600 | Shares Floating 16683445 | ||
Percent Insiders 20.64 | Percent Institutions 56.74 |
Upturn AI SWOT
Acrivon Therapeutics, Inc. Common Stock

Company Overview
History and Background
Acrivon Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for cancer. Founded in 2009, it utilizes its proprietary proteomics-based platform, Acrivon Predictive Precision (APPi), to identify patients most likely to respond to specific drug candidates.
Core Business Areas
- Drug Development: Focuses on the discovery and development of novel therapies for oncology.
- Diagnostic Development: Develops companion diagnostics to identify patients likely to benefit from its therapies.
- APPi Platform: Provides a proteomic screening platform that analyzes a patient's tumor sample to determine if they are likely to respond to the drug.
Leadership and Structure
Dr. Peter Blume-Jensen serves as the President and CEO. The company has a management team with expertise in oncology drug development and diagnostics. It operates as a publicly traded biopharmaceutical company.
Top Products and Market Share
Key Offerings
- ACRN-368: An investigational Chk1/2 inhibitor for the treatment of advanced cancers with specific genetic mutations. It's in clinical development. Competitors include other Chk1/2 inhibitors in development from companies like Merck and Novartis. Market share is currently 0 as it is pre-commercial.
- ACRN-1000: A preclinical protein degrader targeting transcription factor involved in tumor cell growth. Competitors are companies developing similar PROTAC protein degradation technologies, such as Arvinas and C4 Therapeutics. Market share is currently 0 as it is pre-clinical.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in cancer therapies. There's a growing trend towards precision medicine and targeted therapies.
Positioning
Acrivon is positioned as a precision medicine company leveraging its APPi platform to select patients most likely to respond to its drug candidates, aiming for improved efficacy and reduced toxicity.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Acrivon's focus on precision medicine positions it to capture a segment of this market by improving treatment outcomes and potentially reducing healthcare costs through patient selection.
Upturn SWOT Analysis
Strengths
- Proprietary APPi platform for patient selection
- Focus on precision medicine
- Experienced management team
- Novel drug candidates with potential for improved efficacy
Weaknesses
- Limited number of clinical-stage assets
- High cash burn rate typical of biotech companies
- Reliance on successful clinical trial outcomes
- Potential for competition from larger pharmaceutical companies
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of APPi platform to other diseases
- Successful clinical trial results leading to regulatory approval
- Potential for acquisitions
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cancer therapies
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- ARVN
- MRK
- NVS
Competitive Landscape
Acrivon faces competition from established pharmaceutical companies and other biotech companies in the oncology space. Its competitive advantage lies in its APPi platform, which aims to improve patient selection and drug efficacy. Acrivon has no market share as it currently does not have any commercial products.
Growth Trajectory and Initiatives
Historical Growth: Acrivon has focused on research and development, so it does not have a significant growth history yet.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals of its drug candidates. Analyst estimates are highly variable due to the uncertainty of the biotech industry.
Recent Initiatives: Advancement of ACRN-368 and ACRN-1000 through clinical trials, expansion of APPi platform capabilities, and pursuit of strategic partnerships.
Summary
Acrivon Therapeutics is a promising biopharmaceutical company leveraging a proprietary technology platform for precision medicine. Currently its fundamentals are weak, and it faces significant risk due to dependence on clinical trial success and regulatory approvals. The company needs to look out for potential clinical trial failures, competition, and regulatory hurdles. Its strength lies in its APPi platform and novel drug candidates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acrivon Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2022-11-15 | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Dr. Peter Blume-Jensen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 75 | Website https://acrivon.com |
Full time employees 75 | Website https://acrivon.com |
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.